Syntropic Medical, a pioneering medical device company emerging from the Institute of Science and Technology Austria (ISTA), has successfully secured a substantial 7-figure investment. The funding, provided by xista science ventures and aws (the promotional bank of the Austrian federal government), aims to propel the development of an innovative non-invasive and non-pharmaceutical treatment for mental health disorders.

Founded in 2023 by Mark Caffrey, Jack O’Keeffe, Dr. Alessandro Venturino, and Prof. Sandra Siegert, Syntropic Medical stands at the forefront of medical innovation. Their breakthrough technology centers around a unique light-based brain stimulation device, stemming from a light stimulation protocol discovered by the Siegert Group at ISTA. This cutting-edge brain stimulation method is designed to promote microglia-mediated neuroplasticity, potentially revolutionizing the treatment landscape for a spectrum of mental health disorders, including Major Depressive Disorder (MDD).

The motivation behind Syntropic Medical's endeavors is underscored by the limitations of conventional pharmaceutical therapies. Mark Caffrey, CEO of Syntropic Medical, highlights that approximately 70% of patients undergoing pharmaceutical antidepressant treatment fail to achieve remission, with up to 25% discontinuing medication due to severe side effects. Recognizing the imperative for novel treatment modalities, Caffrey emphasizes the significance of the discoveries by Dr. Venturino and Prof. Siegert. Their pioneering work offers a glimpse into a future where patients may access treatments devoid of side effects, offering simplicity and efficacy.

Florian Resch, Managing Partner at xista science ventures, shares in Caffrey's enthusiasm, emphasizing the pivotal role of Syntropic Medical in addressing an urgent market need. By leveraging a neuromodulation-based approach, the company targets a domain ripe for innovation and transformation. The partnership between Syntropic Medical and xista science ventures is poised to usher in a new era of mental health treatment, capitalizing on the groundbreaking research originating from the Siegert Lab at ISTA.

As Syntropic Medical advances its mission to redefine mental health treatment paradigms, the investment injection from xista science ventures and aws underscores a collective commitment to driving tangible change in the field. With a focus on innovation, efficacy, and patient well-being, Syntropic Medical emerges as a beacon of hope for individuals grappling with mental health disorders worldwide.